Cell and Gene Manufacturing and Logistics

31. New Group Wants 'Phase-Appropriate' Thinking To Retire 9/4/2025

    Decisions in cell and gene therapy are not about aligning with arbitrary clinical phases but about balancing risk.

32. Generation Of A Universal AAV Packaging Cell Line For Commercial Gene Therapy Manufacturing 9/4/2025

    Uncover the benefits of this CGMP-ready, stable AAV packaging cell line with proven expertise to reduce costs, streamline manufacturing, and make life-changing gene therapies more accessible to patients in need.

33. Pioneering Affordable CAR-T Cell Therapies In India 9/3/2025

    CAR-T cell therapy is poised to transform cancer care in India, with new initiatives aiming to make this breakthrough treatment both clinically feasible and financially accessible.

34. Using Slot Management To Bridge The Gap Between Capacity And CGTs 9/3/2025

    Optimizing slot management is essential for cell and gene therapy manufacturers to overcome high costs, long turnaround times, and limited patient access by enabling real-time scheduling, better resource utilization, and advanced technology integration.

35. Cell Cycle Mapping In Tumors With Advanced Technologies 9/2/2025

    Discover how spatial profiling and advanced imaging tools are transforming drug discovery, featuring Wayne Stallaert’s lab’s work on cell cycle mapping and biomarker insights in cancer research.

36. Lilly's Exploring A Universal AAV Purification Method 9/2/2025

    Serotype-specific resins don't scale gracefully. One team at Eli Lilly and Company is exploring an alternative that skips affinity resins altogether.

     

37. Addressing Core Requirements In CGT Manufacturing Optimization 9/1/2025

    Discover how a fully automated, standardized approach can enhance biological performance, reduce process timelines, and enable commercial-scale production for cell and gene therapy treatments.

38. Non-Viral Delivery Of Complex Cargos For Large-Scale T-Cell Manufacturing 9/1/2025

    We operate at the forefront of emerging technologies – cell and gene, microbial, mRNA – to help pioneer our customers’ breakthrough medicines. Explore a next-generation large-scale electroporation platform.

39. Challenges In Scaling Allogeneic Processes 9/1/2025

    Learn practical strategies for optimizing harvest, cell separation, and large-volume freezing to ensure process efficiency, reduce risk, and maintain product viability.

40. Aggregation In Antibody-Drug Conjugates: Causes And Mitigation 9/1/2025

    Discover how early intervention in ADC development can streamline clinical progress, ensure stability and safety, and accelerate commercialization with expert guidance.